RONALD B. KALICH - 11 Nov 2022 Form 4 Insider Report for SURMODICS INC (SRDX)

Role
Director
Signature
/s/ John Manders, on behalf of Ronald B. Kalich
Issuer symbol
SRDX
Transactions as of
11 Nov 2022
Net transactions value
-$3,405
Form type
4
Filing time
15 Nov 2022, 15:29:21 UTC
Previous filing
04 Oct 2022
Next filing
03 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRDX Common Stock Options Exercise $88,106 +4,366 +15% $20.18 32,912 11 Nov 2022 Direct
transaction SRDX Common Stock Sale $91,511 -2,733 -8.3% $33.48 30,179 11 Nov 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRDX Stock Option (right to buy) Options Exercise $0 -4,366 -100% $0.000000* 0 11 Nov 2022 Common Stock 4,366 $20.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the weighted average price of 2,733 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on November 11, 2022 with sale prices ranging from $33.40 to $33.95 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2 The amount beneficially owned includes 10,113 restricted stock units (RSUs) that vest on service-based vesting dates and 12,016 DSUs that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends.
F3 Fully vested.